<DOC>
	<DOCNO>NCT03013751</DOCNO>
	<brief_summary>This study 12-month ( 52 week ) safety extension study supplement FUEL Phase III clinical trial provide safety information regard long-term use udenafil adolescent single ventricle congenital heart disease .</brief_summary>
	<brief_title>A Extension Study Udenafil Adolescents</brief_title>
	<detailed_description>This open-label extension study . All enrol subject provide udenafil duration study . Subjects complete Phase III FUEL study eligible recruitment . Additional subject recruit needed ensure minimum 300 total subject enroll . Safety , pharmacodynamic quality life data collect analyzed .</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Udenafil</mesh_term>
	<criteria>1 . Males females Fontan physiology participate FUEL trial , participate FUEL , 12 less 19 year age enrollment . 2 . Participant consent parental/guardian consent participant assent 3 . Participant fluent English , Spanish , Korean 1 . Height &lt; 132 cm . 2 . Weight &lt; 40 kg . 3 . Hospitalization acute decompensated heart failure within last 12 month . 4 . Current intravenous inotropic drug . 5 . Undergoing evaluation heart transplantation list transplantation . 6 . Diagnosis active protein lose enteropathy plastic bronchitis within last three year , history liver cirrhosis . 7 . Known Fontan baffle obstruction , branch pulmonary artery stenosis , pulmonary vein stenosis result mean gradient &gt; 4 mm Hg region proximal distal obstruction measure either catheterization echocardiography . 8 . Single lung physiology . 9 . Maximal VO2 le 50 % predict age gender enrollment . 10 . Severe ventricular dysfunction assess qualitatively clinical echocardiography within six month prior enrollment . 11 . Severe valvar regurgitation , ventricular outflow obstruction , aortic arch obstruction assess clinical echocardiography within six month prior enrollment . 12 . Significant renal , hepatic , gastrointestinal biliary disorder could impair absorption , metabolism excretion orally administer medication . 13 . Inability complete exercise test baseline screening . 14 . History PDE5 inhibitor use ( exception FUEL participation ) within 3 month study onset . 15 . Use drug treat pulmonary hypertension within 3 month study onset . 16 . Known intolerance oral udenafil . 17 . Frequent use medication substance inhibit induce CYP3A4 . 18 . Current use alphablockers nitrate . 19 . Ongoing plan participation another research protocol would either prevent successful completion plan study test invalidate result . 20 . Noncardiac medical , psychiatric , and/or social disorder would prevent successful completion plan study test would invalidate result . 21 . Cardiac care , ongoing plan , nonstudy center would impede study completion . 22 . For female : Pregnancy time screening , pregnancy plan study completion , refusal use acceptable method contraception study duration . 23 . Unable abstain limit intake grapefruit juice duration trial . 24 . Refusal provide write informed consent/assent . 25 . In opinion primary care physician , subject likely noncompliant study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>